Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gilotrif Approval Gives Boehringer Milestone, But Can It Compete With Tarceva?

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA approval of its first oncology drug is a victory for Boehringer Ingelheim. Now comes another challenge – a commercial battle with Roche’s Tarceva, which is firmly established across lines of therapy for EGFR-positive lung cancer patients.


Related Content

Boehringer Joins Next Generation Via Hanmi EGFR Inhibitor Deal
Broader Indications For Tarceva As Astellas Scales Back In The U.S.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts